All In Biotech

Drug Trial Radar · NCT07780669

A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants 40 to 80 Years of Age With Moderate to Very Severe COPD (PERSIST COPD-1)

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 624 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

624

Planned (sponsor's estimate)

Start

Aug 27, 2026

Primary completion

Jul 20, 2029

Study completion Mar 15, 2030

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Aug 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • GSK5784283Drug

    GSK5784283 will be administered.

  • PlaceboDrug

    Placebo will be administered.

  • Standard of careDrug

    Standard of care will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized rate of moderate or severe COPD ExacerbationsTime frame: Up to Week 78

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Doral, Florida · Recruiting

  • GSK Investigational Site

    Derby, Kansas · Recruiting

  • GSK Investigational Site

    Lake Charles, Louisiana · Recruiting

  • GSK Investigational Site

    Staten Island, New York · Recruiting

  • GSK Investigational Site

    Humble, Texas · Recruiting

  • GSK Investigational Site

    Huntsville, Texas · Recruiting

  • GSK Investigational Site

    West Jordan, Utah · Recruiting

  • GSK Investigational Site

    Fukuoka, Japan · Recruiting

  • GSK Investigational Site

    Fukuoka, Japan · Recruiting

  • GSK Investigational Site

    Ishikawa, Japan · Recruiting

  • GSK Investigational Site

    Tokyo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.